Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (6): 81-86.doi: 10.6040/j.issn.1671-7554.0.2018.1481

Previous Articles    

Correlation between SUVmax of 18F-FDG PET/CT and programmed cell death-ligand 1 expression in lung cancer patients: a Meta-analysis

CHEN Hongyan1, MA Yuanyuan2, SUN Hukui2   

  1. 1. Respiratory Department, Chest Hospital of Shandong Province, Jinan 250013, Shandong, China;
    2. Nuclear Medicine Department, Central Hospital of Zibo, Zibo 255000, Shandong, China
  • Published:2022-09-27

PDF (PC)

4

Abstract: Objective To study the correlation between 18F-FDG uptake and programmed cell death-ligand 1(PD-L1)expression in lung cancer patients by Meta-analysis of published articles. Methods According to the literature inclusion and exclusion criteria, PubMed(MEDLINE included), EMBASE, and Cochrane Database of Systematic Review were searched, and research articles on the relationship between 18F-FDG uptake and PD-L1 expression, which were published between January 1, 2000 and Decenber 1, 2018, were selected. The quality of included articles was evaluated according to the Jadad scale. The correlation coefficient(r)was extracted from the included articles. The combined r and the 95% confidence interval (CI) were calculated with Comprehensive Meta-Analysis software under a random-effects model. Results According to the inclusion and exclusion criteria, 4 articles, involving 1033 patients, were finally included. All the studies had a combined r value of 0.289(95%CI: 0.100~0.459, P<0.001), but with a significant 山 东 大 学 学 报 (医 学 版)57卷6期 -陈红艳,等.肺癌患者18F-FDG PET/CT SUVmax与程序性死亡受体-配体1表达相关性的Meta分析 \=-heterogeneity(I2=86%, P=0.003). Subgroup analysis for different tumor types indicated that adenocarcinomas and squamous cell carcinomas showed a positive correction(r=0.273, P=0.003; r=0.235, P=0.001). Conclusion SUVmax positively correlates with PD-L1 expression for patients with lung cancer, and the similar trend is found in both adenocarcinomas and squamous cell carcinomas. The assessment of SUVmax value and PD-L1 immunohistochemistry score may improve the accuracy of patient selection and predicit PD-1 treatment effect.

Key words: Lung cancer, Programmed cell death-ligand1, SUVmax, Meta analysis, Spearman correlation coefficient

CLC Number: 

  • R734.2
[1] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Sher DJ, Koshy M, Liptay MJ, et al. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base[J]. Cancer, 2014, 120(13): 2060-2068.
[3] Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013[J]. J Natl Compr Canc Netw, 2013, 11(6): 645-653; quiz 653.
[4] Lim SH, Sun JM, Lee SH, et al. Pembrolizumab for the treatment of non-small cell lung cancer[J]. Expert Opin Biol Ther, 2016, 16(3): 397-406.
[5] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
[6] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550.
[7] Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer[J]. J Thorac Oncol, 2016, 11(7): 976-988.
[8] Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments[J]. Eur J Nucl Med Mol Imaging, 2017, 44(Suppl 1): 55-66.
[9] Higuchi M, Owada Y, Inoue T, et al. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer[J]. World J Surg Oncol, 2016, 14(1): 238. doi:10.1186/s12957-016-0998-y.
[10] Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale[J]. Control Clin Trials, 1999, 20(5): 448-452.
[11] Chalkidou A, Landau DB, Odell EW, et al. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis[J]. Eur J Cancer, 2012, 48(18): 3499-3513.
[12] Landis JR, Koch GG. The measurement of observer agreement for categorical data[J]. Biometrics, 1977, 33(1): 159-174.
[13] Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer(NSCLC)who are candidates for upfront surgery[J]. Eur J Nucl Med Mol Imaging, 2016, 43(11): 1954-1961.
[14] Zhang MH, Wang DL, Sun Q, et al. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma[J]. Oncotarget, 2017, 8(31): 51630-51640.
[15] Takada K, Toyokawa G, Okamoto T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18F-fluorodeoxyglucose positron emission tomography/computed tomography[J]. Cancer Med, 2017, 6(11): 2552-2561.
[16] Kaira K, Shimizu K, Kitahara S, et al. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma[J]. Eur J Cancer, 2018, 101: 181-190. doi:10.1016/j.ejca.2018.06.022.
[17] Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies[J]. Ann Oncol, 2016, 27(1): 147-153.
[18] Cooper WA, Tran T, Vilain RE, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma[J]. Lung Cancer, 2015, 89(2): 181-188.
[19] Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2): 208-222.
[20] Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2012, 39(1): 27-38.
[21] Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT[J]. Lung Cancer, 2013, 79(3): 242-247.
[22] Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J]. Clin Cancer Res, 2004, 10(15): 5094-5100.
[23] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
[24] Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer[J]. Cancer Res, 2013, 73(8): 2381-2388.
[25] Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer(NSCLC)who are candidates for upfront surgery[J]. Eur J Nucl Med Mol Imaging, 2016, 43(11): 1954-1961.
[1] HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118.
[2] GAO Zhongxia, ZHANG Ming, FAN Mingde, TAN Chenyang, WANG Mengdi, WANG Chao, FAN Yuefei, DING Shouluan, WANG Chengwei. Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 44-49.
[3] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[4] WANG Fuli, SUN Yinping, QIN Jie, RONG Jiansheng. Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 110-117.
[5] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[6] Jinming YU,Weiwei YAN,Dawei CHEN. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[7] ZHANG Yu, TANG Xing, MA Haitao, JIANG Wei. Value of indocyanine green fluorescence in thoracoscopic segmentectomy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 38-42.
[8] ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46.
[9] LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.
[10] WANG Cong, ZHU Ling, WAN Yunyan, YAO Zhouhong, LI Dezhi, XU Xiaoting, XU Pengfei, LIN Dianjie. Therapeutic effect of different administration ways of recombinant human endostatin combined with cisplatin on Lewis lung cancer xenografts in mice [J]. Journal of Shandong University (Health Sciences), 2019, 57(5): 93-98.
[11] WEI Ping, DU Lutao, WANG Qing, ZHAN Yao, XIE Yujiao, ZHANG Shujun, DUAN Weili, WANG Chuanxin. Diagnostic value of serum exosomal miR-20b-5p for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 91-96.
[12] ZHANG Zhihui, LIU Yanguo, XIAO Fengqi, MA Daoxin, WANG Xiuwen. Effect of cisplatin on IL-6 expression in tumor mesenchymal stem cells and underlying mechanism of p38MAPK pathway [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 1-6.
[13] WANG Wei, LIU Yongzheng, LI Ling. Effects of Physalin B on proliferation, migration and apoptosis of human non-small cell lung cancer cells [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 13-18.
[14] JIANG Yunfeng, DONG Xiaopeng, ZHAO Xiaogang. Combinatorial anti-PD-1 and endostatin therapeutic efficacy in Lewis lung cancer mice [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 11-16.
[15] . Expert consensus on laboratory diagnosis of lung cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 9-17.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd